Skip to main content
OpenTrials
Completed

NCT Number: NCT00680927

Reveal® XT Performance Trial (XPECT)

The purpose of this study is to quantify the accuracy of the atrial fibrillation diagnostics of the Reveal® XT in a clinical setting and to verify overall system performance, R-wave sensing performance, to obtain user feedback, from both patient and physician, and collect data on device safety.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atrial Fibrillation Arrhythmias, Cardiac Cardiovascular Diseases Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Risk of Cardiac Arrhythmias

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

LKH - Universitätskliniken, Innsbruck, Austria

Loading trial locations.

About this study

The study is a prospective, non-randomized, multi-center international post-market study.

The study will be conducted at 20-30 centers primarily in Europe. The study will be conducted at least in Germany, Austria, Switzerland, The Netherlands, and the Czech Republic. Study centers from Canada may also participate, depending on the timelines for regulatory approval and commercial release of the Reveal® XT in this region.

It is expected that between 140 and 200 patients will be enrolled to ensure that at least 47 patients are included to assess the first primary objective and at least 60 patients to assess the second primary objective.

The primary objective is to quantify the AF detection performance of the device.

The patient population will be assessed in two separate cohorts. The first primary objective is to quantify the 24-hour AF burden accuracy in patients with more than 1% AF burden.

The second primary objective is to quantify the detection accuracy of non-arrhythmia in patients with 1% or less AF burden.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient is willing and able to provide his/her informed consent
  • Patient has been implanted with a Reveal® XT
  • Patient fulfills at least one of the following three additional requirements
  • is scheduled for PV ablation or surgical rhythm control intervention, and the PV ablation or surgical intervention can be deferred until study completion or
  • has documented frequent AF or frequent symptoms attributable to AF or
  • has undergone PV ablation within the last 6 months and still has symptoms attributable to AF

Exclusion criteria

  • Patient has an implanted pacemaker or ICD
  • Patient has persistent or permanent AF
  • Patient is allergic to adhesive ECG electrodes
  • The study will interfere with a therapeutic or diagnostic procedure which is planned or expected during the study period
  • Patient is participating in another study that is expected to compromise the results of this study
  • Patient is a minor, legally incompetent, or does not meet other local requirements for participation in a clinical study
  • Patient is pregnant

Treatment and study plan

46 hrs Holter ECG recording

Other

Maximum of 2 46 hrs external Holter ECG recordings are required.

Primary outcomes

  1. Atrial Fibrillation Burden (AF Burden)

    Time frame: 46 hrs

Secondary outcomes

  1. AF episode detection accuracy and AF episode duration accuracy

    Time frame: 46 hrs

Sponsors and collaborators

Lead sponsor

Medtronic BRC

Industry

Registry information

Official study title

Reveal® XT Performance Trial

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
May 20, 2008
Registry last updated
Jun 3, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.